Orchard Therapeutics Future Growth
Future criteria checks 2/6
Orchard Therapeutics is forecast to grow earnings and revenue by 12.5% and 34.5% per annum respectively while EPS is expected to grow by 55.2% per annum.
Key information
12.5%
Earnings growth rate
55.2%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 34.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Dec 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 152 | -50 | -106 | N/A | 2 |
12/31/2025 | 97 | -75 | -148 | N/A | 2 |
12/31/2024 | 54 | -115 | -129 | -114 | 3 |
12/31/2023 | 28 | -93 | -85 | -85 | 3 |
9/30/2023 | 22 | -73 | -94 | -93 | N/A |
6/30/2023 | 21 | -85 | -93 | -87 | N/A |
3/31/2023 | 18 | -124 | -93 | -86 | N/A |
12/31/2022 | 23 | -151 | -83 | -76 | N/A |
9/30/2022 | 16 | -179 | -104 | -97 | N/A |
6/30/2022 | 12 | -168 | -100 | -96 | N/A |
3/31/2022 | 7 | -154 | -109 | -105 | N/A |
12/31/2021 | 2 | -145 | -128 | -125 | N/A |
9/30/2021 | 1 | -142 | -106 | -104 | N/A |
6/30/2021 | 2 | -126 | -115 | -114 | N/A |
3/31/2021 | 3 | -137 | -117 | -116 | N/A |
12/31/2020 | 3 | -152 | -139 | -126 | N/A |
9/30/2020 | 3 | -164 | -171 | -155 | N/A |
6/30/2020 | 3 | -180 | -197 | -181 | N/A |
3/31/2020 | 3 | -183 | -187 | -172 | N/A |
12/31/2019 | 3 | -163 | -170 | -166 | N/A |
9/30/2019 | 3 | -143 | -153 | -151 | N/A |
6/30/2019 | 2 | -140 | -131 | -130 | N/A |
3/31/2019 | 2 | -246 | -129 | -127 | N/A |
12/31/2018 | 2 | -230 | -102 | -98 | N/A |
9/30/2018 | 1 | -219 | -85 | -81 | N/A |
6/30/2018 | N/A | -198 | -63 | -59 | N/A |
3/31/2018 | N/A | -48 | -43 | -40 | N/A |
12/31/2017 | N/A | -40 | -34 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OT10 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OT10 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OT10 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OT10's revenue (34.5% per year) is forecast to grow faster than the German market (4.4% per year).
High Growth Revenue: OT10's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OT10's Return on Equity is forecast to be high in 3 years time